Next Article in Journal
Non-Cytotoxic Agarose/Hydroxyapatite Composite Scaffolds for Drug Release
Next Article in Special Issue
Evaluation of the Common Molecular Basis in Alzheimer’s and Parkinson’s Diseases
Previous Article in Journal
Neuroprotective Potential of GDF11: Myth or Reality?
Previous Article in Special Issue
Searching for Potential Lipid Biomarkers of Parkinson’s Disease in Parkin-Mutant Human Skin Fibroblasts by HILIC-ESI-MS/MS: Preliminary Findings
Open AccessReview

Alteration of Sphingolipids in Biofluids: Implications for Neurodegenerative Diseases

Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas (CIDIE-CONICET), X5016DHK Córdoba, Argentina
Int. J. Mol. Sci. 2019, 20(14), 3564; https://doi.org/10.3390/ijms20143564
Received: 15 June 2019 / Revised: 12 July 2019 / Accepted: 13 July 2019 / Published: 21 July 2019
(This article belongs to the Special Issue Lipidomics and Neurodegenerative Diseases)
Sphingolipids (SL) modulate several cellular processes including cell death, proliferation and autophagy. The conversion of sphingomyelin (SM) to ceramide and the balance between ceramide and sphingosine-1-phosphate (S1P), also known as the SL rheostat, have been associated with oxidative stress and neurodegeneration. Research in the last decade has focused on the possibility of targeting the SL metabolism as a therapeutic option; and SL levels in biofluids, including serum, plasma, and cerebrospinal fluid (CSF), have been measured in several neurodegenerative diseases with the aim of finding a diagnostic or prognostic marker. Previous reviews focused on results from diseases such as Alzheimer’s Disease (AD), evaluated total SL or species levels in human biofluids, post-mortem tissues and/or animal models. However, a comprehensive review of SL alterations comparing results from several neurodegenerative diseases is lacking. The present work compiles data from circulating sphingolipidomic studies and attempts to elucidate a possible connection between certain SL species and neurodegeneration processes. Furthermore, the effects of ceramide species according to their acyl-chain length in cellular pathways such as apoptosis and proliferation are discussed in order to understand the impact of the level alteration in specific species. Finally, enzymatic regulations and the possible influence of insulin resistance in the level alteration of SL are evaluated. View Full-Text
Keywords: neurodegeneration; lipidomics; ceramides; sphingomyelin; biofluids; apoptosis neurodegeneration; lipidomics; ceramides; sphingomyelin; biofluids; apoptosis
Show Figures

Figure 1

MDPI and ACS Style

Pujol-Lereis, L.M. Alteration of Sphingolipids in Biofluids: Implications for Neurodegenerative Diseases. Int. J. Mol. Sci. 2019, 20, 3564.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop